A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

NCT07362459 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Carcinoma (NSCLC)

Interventions

DRUG: SCTB14
DRUG: Pembrolizumab

Sponsor

Sinocelltech Ltd.